Fig. 2.

Setd2 mutants cooperate with the Mll-Af9 knock-in allele to accelerate leukemia. a H3K36me3 levels in c-Kit positive bone marrow cells from Mll-Af9/Setd2^WT/WT, Mll-Af9/Setd2^F2478L/WT, and Mll-Af9/Setd2^Ex6-KO/WT mice at 6 months, the end stage of leukemia. b CFU replating assays of bone marrow cells from Mll-Af9 and two Mll-Af9/ Setd2-mutant mice. c Cell number counts of CFUs in the serial replating in (b). d Cell number counts of serial replating of CD34 MLL-AF9/Scrambled and CD34 MLL-AF9/shSETD2 cells. Three biological replicates of each genotype are performed in triplicate and the data are presented as the mean ± SD values. *P < 0.05; **P < 0.01; ***P < 0.001. e Survival curves for Mll-Af9 (n = 16) and Mll-Af9/ Setd2^Ex6-KO/WT (n = 20) transgenic mutant mice, regardless of gender. f Survival curves for NSGS mice receiving bone marrow transplantation with CD34 MLL-AF9/Scrambled (n = 4) or CD34 MLL-AF9/ shSETD2 (n = 4) cells